Gabrail Cancer Center Research
Gabrail Cancer Center Research
Canton, Ohio, United States26 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 1 / Phase 2 | 2026-10-08 | NCT07864584 | |
| A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions | Hemic and Lymphatic Diseases, anemia, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Recruiting | Phase 3 | 2026-10-08 | NCT06499285 | |
| Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer | Metastatic Pancreatic Adenocarcinoma | Recruiting | Phase 3 | 2026-10-07 | NCT01954992 | |
| A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes, Genital Diseases, Kennedy disease, Male Urogenital Diseases, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Urogenital Diseases, Urogenital Neoplasms, X-linked disease, central nervous system disorder, hereditary disease, inherited neurodegenerative disorder, male reproductive organ cancer, male reproductive system disorder, motor neuron disorder, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, prostate cancer, prostate disorder, spinal cord disorder, spinal muscular atrophy | Recruiting | Phase 3 | 2026-10-05 | NCT07723248 | |
| INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV) | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, bone marrow disorder, bone marrow neoplasm, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Recruiting | Phase 3 | 2026-10-05 | NCT07429266 | |
| A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-10-05 | NCT04224493 | |
| BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, peripheral neuropathy, rectal disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-29 | NCT05322590 | |
| This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-25 | NCT06758401 | |
| Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, anemia, bone marrow disorder, hematologic disorder, myelodysplastic syndrome, primary myelofibrosis | Recruiting | Phase 1 / Phase 2 | 2026-09-23 | NCT05320198 | |
| Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-09-22 | NCT06712316 | |
| Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-16 | NCT04486833 | |
| Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients | Small Cell Lung Cancer Extensive Stage | Recruiting | Phase 1 / Phase 2 | 2026-09-11 | NCT05703971 | |
| Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Recruiting | Phase 2 | 2026-09-01 | NCT05727176 | |
| A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm | Enrolling by invitation | Phase 2 | 2026-07-28 | NCT04093570 | |
| A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2026-07-22 | NCT05253651 | |
| A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 / Phase 3 | 2026-07-15 | NCT05800015 | |
| A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | Advanced Non-Small Cell Lung Cancer | Active, not recruiting | Phase 2 / Phase 3 | 2026-07-02 | NCT05785767 | |
| A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-05-26 | NCT05668988 | |
| A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | Active, not recruiting | Phase 3 | 2026-05-06 | NCT06311721 | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | B-cell neoplasm, Bites and Stings, Cancer of the Uterine Cervix, Chemically-Induced Disorders, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, Uveal Neoplasms, benign urinary system neoplasm, breast disorder, breast neoplasm, carcinoma, cervix disorder, diffuse large B-cell lymphoma, epithelial neoplasm, eye disorder, female reproductive system disorder, female reproductive system neoplasm, follicular lymphoma, head and neck squamous cell carcinoma, immune system disorder, immunoproliferative disorder, in situ carcinoma, injury, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, melanocytic neoplasm, melanoma, metastatic malignant neoplasm, neoplasm, neuroendocrine neoplasm, ocular cancer, poisoning, primitive neuroectodermal tumor, skin disorder, skin neoplasm, squamous cell carcinoma, triple-negative breast carcinoma, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine disorder, uveal disorder, uveal melanoma | Recruiting | Phase 1 | 2025-12-24 | NCT06022029 | |
| A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-10-24 | NCT06228326 | |
| A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors | Solid Tumor | Active, not recruiting | Phase 1 | 2025-10-20 | NCT05627063 | |
| Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, brain disorder, central nervous system cancer, central nervous system disorder, melanocytic neoplasm, melanoma, neoplasm, nervous system disorder, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Active, not recruiting | Phase 3 | 2025-09-24 | NCT04674683 | |
| A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, cancer, cutaneous melanoma, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-05-18 | NCT05970497 | |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Active, not recruiting | Phase 3 | 2024-12-31 | NCT04691804 |